GlobeNewswire

Cryptomining Replaces Ransomware as Most Popular Cybercrime Malware

Dela

Analysis of vulnerability and threat trends shows cryptomining malware dominates threat landscape in the first half of 2018

SAN JOSE, Calif., July 18, 2018 (GLOBE NEWSWIRE) -- Skybox® Security, a global leader in cybersecurity management, announced today the release of its mid-year update to the Vulnerability and Threat Trends Report which analyzes vulnerabilities, exploits and threats in play. The report, compiled by the team of security analysts at the Skybox® Research Lab, aims to help organizations align their security strategy with the reality of the current threat landscape.

The mid-year update explores trends observed from January to June of 2018. One of the most significant findings is the replacement of ransomware as the cybercriminal tool of choice with cryptomining malware. In the last six months of 2017, ransomware accounted for 32 percent of attacks, while malicious cryptominers accounted for seven percent. By the first half of 2018, the figures had switched almost exactly: malicious cryptominers accounted for 32 percent of attacks while ransomware dropped to eight percent.

"In the last few years, ransomware reigned supreme as the shortcut money-maker for cybercriminals," said Ron Davidson, Skybox CTO and vice president of R&D. "It doesn't require data exfiltration, just encryption to hold the data hostage and a ransom note of how the victim can pay up. With cryptominers, the criminals can go straight to the source and mine cryptocurrency themselves. There's no question of if they'll be paid or not."

Cryptomining uses the computational power of compromised assets to create new blocks in the blockchain of like Bitcoin and Monero. The malicious or unauthorized cryptomining approach indeed avoids several of the drawbacks of ransomware:

  • The victim doesn't need to be notified of the attack in order to pay the ransom, so it can continue indefinitely in a stealth manner
  • Cryptocurrency can be mined over long-periods of time, rather than the cybercriminal receiving a single lump-sum ransom payment
  • There is no decision of payment on the part of the victim - the attack itself controls how much money will be generated.

"Ransomware received a lot of attention in years past, especially thanks to the likes of WannaCry, NotPetya and BadRabbit," said Skybox Director of Threat Intelligence Marina Kidron and leader of the Research Lab behind the report. "To some extent, organizations took note and put effective precautions in place, ensuring they had reliable back-ups and even thwarting attackers with decryption programs. So cybercriminals found - in cryptomining- a path of lesser resistance. The recent uptick in value of cryptocurrencies also made this an incredibly profitable attack option."

Other findings in the report appear to relate to this rise in cryptomining. Internet and mobile vulnerabilities made up nearly a third of all new vulnerabilities published in the first half of 2018. Google Android had by far the most vulnerabilities during that time period, exceeding the tally of the next five most vulnerable vendors combined. Android also logged 200 more vulnerabilities than it did in the second half of 2018. Malicious cryptomining has found an advantage in targeting the app store of the global market leader in mobile devices, with billions of potential targets worldwide.

Browser-based malware is also on the rise in the first half of 2018. "Out of all software today, web browsers are considered the most prone to malicious attacks," said Kidron. "They constantly interact with websites and applications that cybercriminals have infected with malware like cryptominers and other threats via the web, which are notoriously difficult to detect. The cryptomining malware could be active as long as the web session is active, and 'file-less' cryptominers also can hide from conventional security tools as there's no download or attachment to analyze."

No matter the payload, attackers looking to exploit vulnerabilities have more resources than ever. Not only are dark web market places rich with attack tools and services, and criminal forums ripe with information, vulnerabilities themselves have skyrocketed. New vulnerabilities catalogued by MITRE's National Vulnerability Database doubled in 2017 over the previous year, and 2018 looks to be on track to shatter even that record. The 2017 surge and continued elevated numbers is largely due to organizational improvements at MITRE and increased security research by vendors and third-parties, including vendor-sponsored bug bounty programs. But no matter the reason, organizations have to employ smarter and faster ways to find the signal in the noise and mitigate vulnerability risks before they're used in an attack.

Skybox recommends establishing a threat-centric vulnerability management (TCVM) program to adapt to these changes in the threat landscape and those yet to come. The TCVM approach helps security practitioners focus on the small subset of vulnerabilities most likely to be used in an attack by incorporating vulnerability and threat intelligence with the context of their assets, network and security controls. This way, remediation is targeted at the greatest areas of risk while leveraging all response options - patching as well as network-based changes.

To read the full report on vulnerability and threat trends thus far in 2018, click here. To learn more about Skybox vulnerability management approach, download our e-book here

About Skybox Research Lab 
The Skybox Research Lab is team of security analysts who daily scour data from dozens of security feeds and sources as well as investigate sites in the dark web. The Research Lab validates and enhances data through automated as well as manual analysis, with analysts adding their knowledge of attack trends, cyber events and TTPs of today's attackers. Their ongoing investigations determine which vulnerabilities are being exploited in the wild and used in distributed crimeware such as ransomware, malware, exploit kits and other attacks exploiting client- and server-side vulnerabilities.

For more information on the methodology behind the Skybox Research Lab and to keep up with the latest vulnerability and threat intelligence, visit www.vulnerabilitycenter.com.

About Skybox Security

Skybox provides the industry's broadest cybersecurity management platform to address security challenges within large, complex networks. By integrating with 120 networking and security technologies, the Skybox® Security Suite gives comprehensive attack surface visibility and the context needed for informed action. Our analytics, automation and intelligence improve the efficiency and performance of security operations in vulnerability and threat management and firewall and security policy management for the world's largest organizations.

© 2018 Skybox Security, Inc. All rights reserved. Skybox Security and the Skybox Security logo are either registered trademarks or trademarks of Skybox Security, Inc., in the United States and/or other countries. All other trademarks are the property of their respective owners. Product specifications subject to change at any time without prior notice.

CONTACT INFORMATION

Skybox Security
Tawnya Lancaster
Director of Brand and Communications
408-205-1618 | Tawnya.lancaster@skyboxsecurity.com

OneChocolate for Skybox Security
United Kingdom: Daniel Couzens
+44 (0)20 7437 0227 | DanielC@onechocolatecomms.co.uk

Germany: Melanie Grasser
+49 (0)89 3888 920 10 | MelanieG@onechocolatecomms.de

France: Xavier Delhôme
+33 1 41 31 75 09 | xavier@onechocolate.fr

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8c26e3be-8dd4-457a-b19b-becd7c28c469




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Skybox Security via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum